Genentech defends breast cancer drug a decade after Avastin drama
"We all want to give patients hope — real hope, not false hope," said one opponent of allowing Genentech's Tecentriq to stay on the market.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Avastin | Breast Cancer | Cancer | Cancer & Oncology | Health Management | Pharmaceuticals